- Home
- SOL vs IVA Comparison
SOL vs IVA Comparison
Compare SOL & IVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SOL
- IVA
- Stock Information
- Founded
- SOL 2005
- IVA 2011
- Country
- SOL United States
- IVA France
- Employees
- SOL N/A
- IVA N/A
- Industry
- SOL Semiconductors
- IVA Biotechnology: Pharmaceutical Preparations
- Sector
- SOL Technology
- IVA Health Care
- Exchange
- SOL Nasdaq
- IVA Nasdaq
- Market Cap
- SOL 109.2M
- IVA 117.3M
- IPO Year
- SOL 2008
- IVA 2020
- Fundamental
- Price
- SOL $2.00
- IVA $2.68
- Analyst Decision
- SOL Buy
- IVA Strong Buy
- Analyst Count
- SOL 3
- IVA 4
- Target Price
- SOL $3.83
- IVA $14.00
- AVG Volume (30 Days)
- SOL 218.5K
- IVA 49.5K
- Earning Date
- SOL 11-14-2024
- IVA 09-25-2024
- Dividend Yield
- SOL N/A
- IVA N/A
- EPS Growth
- SOL N/A
- IVA N/A
- EPS
- SOL N/A
- IVA N/A
- Revenue
- SOL $103,577,000.00
- IVA $20,652,523.00
- Revenue This Year
- SOL $44.70
- IVA N/A
- Revenue Next Year
- SOL $20.53
- IVA $361.78
- P/E Ratio
- SOL N/A
- IVA N/A
- Revenue Growth
- SOL 7.56
- IVA N/A
- 52 Week Low
- SOL $1.41
- IVA $1.53
- 52 Week High
- SOL $3.00
- IVA $4.75
- Technical
- Relative Strength Index (RSI)
- SOL 34.81
- IVA 55.41
- Support Level
- SOL $2.00
- IVA $2.52
- Resistance Level
- SOL $2.18
- IVA $2.85
- Average True Range (ATR)
- SOL 0.15
- IVA 0.15
- MACD
- SOL -0.06
- IVA -0.02
- Stochastic Oscillator
- SOL 0.00
- IVA 43.28
About SOL Emeren Group Ltd each representing 10 shares
Emeren Group Ltd is a renewable energy producer. Its portfolio consists of solar projects and Independent Power Producer (IPP) assets, and it also has global Battery Energy Storage System (BESS) capacity. The group specializes in the solar project lifecycle, development, and from construction to financing. It has three reportable segments; Solar power project development, EPC services, and Electricity generation. The company generates maximum revenue from Poland.
About IVA Inventiva S.A. American Depository Shares
Inventiva SA is a France-based biopharmaceutical company specialized in developing drugs that impact on nuclear receptors, transcription factors and epigenetic modulation. The company is focused on developing its product candidate, lanifibranor, for the treatment of patients with non-alcoholic steatohepatitis, or NASH, a disease for which there are currently no approved therapies. The company is also involved in developing a portfolio of pre-clinical therapy programs. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France. Majority of the group's revenue is derived from its research partnerships with AbbVie and BI.